Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study

[1]  J. De Sutter,et al.  Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. , 2017, Global heart.

[2]  H. Støvring,et al.  Statin prescribing according to gender, age and indication: what about the benefit-risk balance? , 2016, Journal of evaluation in clinical practice.

[3]  A. Wierzbicki,et al.  Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough , 2015, BMJ Open.

[4]  V. Fuster,et al.  Global burden of CVD: focus on secondary prevention of cardiovascular disease. , 2015, International journal of cardiology.

[5]  S. Boekholdt,et al.  Adherence to guidelines to prevent cardiovascular diseases: The LifeLines cohort study. , 2015, The Netherlands journal of medicine.

[6]  F. Buntinx,et al.  The correlation between blood pressure and kidney function decline in older people: a registry-based cohort study , 2015, BMJ Open.

[7]  Mark D. Huffman,et al.  Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999–2012 , 2015, Journal of the American Heart Association.

[8]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2014, Journal of the American Pharmacists Association : JAPhA.

[9]  Geert Goderis,et al.  The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project , 2014, BMC Medical Informatics and Decision Making.

[10]  G. Chodick,et al.  Trends in statin therapy initiation during the period 2000–2010 in Israel , 2014, European Journal of Clinical Pharmacology.

[11]  C. Torp-Pedersen,et al.  Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus , 2014, BMC Cardiovascular Disorders.

[12]  K. H. Åsberg,et al.  Trends in Stroke Treatment and Outcome between 1995 and 2010: Observations from Riks-Stroke, the Swedish Stroke Register , 2013, Cerebrovascular Diseases.

[13]  J. H. Park,et al.  Socioeconomic deprivation does not affect prescribing of secondary prevention in patients with peripheral arterial disease. , 2013, International angiology : a journal of the International Union of Angiology.

[14]  N. Wong,et al.  Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007-2010). , 2013, The American journal of cardiology.

[15]  N. Wong,et al.  Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status , 2013, Diabetes & vascular disease research.

[16]  C. Hendriksen,et al.  Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. , 2012, Health policy.

[17]  Y. Béjot,et al.  Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  J. Potter,et al.  The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. , 2012, The American journal of geriatric pharmacotherapy.

[19]  Manesh R. Patel,et al.  Missed Opportunities: Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains , 2012, Circulation.

[20]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[21]  Tatjana Rundek,et al.  Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. , 2012, Archives of internal medicine.

[22]  M. Landray,et al.  Underuse of statins in patients with atherosclerotic ischemic stroke in China. , 2012, Chinese medical journal.

[23]  G. D. De Meyer,et al.  POTENTIAL IMPACT OF POLICY REGULATION AND GENERIC COMPETITION ON SALES OF CHOLESTEROL LOWERING MEDICATION, ANTIDEPRESSANTS AND ACID BLOCKING AGENTS IN BELGIUM , 2012, Acta clinica Belgica.

[24]  G. De Backer,et al.  [New European guidelines for the management of dyslipidaemia in cardiovascular prevention]. , 2012, Revue medicale de Liege.

[25]  T. Marshall,et al.  Patient and Other Factors Influencing the Prescribing of Cardiovascular Prevention Therapy in the General Practice Setting With and Without Nurse Assessment , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  Simon Capewell,et al.  Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. , 2010, American journal of preventive medicine.

[27]  Eric E. Smith,et al.  Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Patients With Stroke , 2010, Stroke.

[28]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[29]  B. Golomb,et al.  Statin‐Associated Adverse Cognitive Effects: Survey Results from 171 Patients , 2009, Pharmacotherapy.

[30]  D. Federman,et al.  Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy , 2009, Vascular medicine.

[31]  H. Støvring,et al.  Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. , 2008, British journal of clinical pharmacology.

[32]  Deepak L. Bhatt,et al.  Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. , 2008, American heart journal.

[33]  B. Hoogwerf,et al.  Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. , 2008, Journal of women's health.

[34]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[35]  C B Dean,et al.  Generalized linear mixed models: a review and some extensions , 2007, Lifetime data analysis.

[36]  P. Giusti,et al.  Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003 , 2007, European Journal of Clinical Pharmacology.

[37]  L. Goldstein,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006 .

[38]  L. Køber,et al.  Statin use after acute myocardial infarction: a nationwide study in Denmark. , 2005, British journal of clinical pharmacology.

[39]  H. Ong.  The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. , 2005, QJM : monthly journal of the Association of Physicians.

[40]  S. Bustacchini,et al.  Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy , 2005, European Journal of Clinical Pharmacology.

[41]  M. Silver,et al.  Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. , 2004, The American journal of cardiology.

[42]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). , 2004, Archives des maladies du coeur et des vaisseaux.

[43]  M. Mamdani,et al.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. , 2004, JAMA.

[44]  S. Tonstad,et al.  Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001 , 2004, Journal of internal medicine.

[45]  L. Mosca,et al.  Is Diabetes Mellitus a Cardiovascular Disease Risk Equivalent for Fatal Stroke in Women?: Data From the Women’s Pooling Project , 2003, Stroke.

[46]  D G Cook,et al.  Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? , 2003, Heart.

[47]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[48]  J. Tu,et al.  Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. , 2003, Archives of internal medicine.

[49]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[50]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[51]  P. Whincup,et al.  Low prevalence of lipid lowering drug use in older men with established coronary heart disease , 2002, Heart.

[52]  Hyune-Ju Kim,et al.  Kim H-J, Fay MP, Feuer EJ, Midthune DN, ‘ Permutation tests for joinpoint regression with applications to cancer rates’. Statistics in Medicine 2000 19:335–351 , 2001 .

[53]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[54]  D. Gordon,et al.  Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. , 1998, Archives of internal medicine.

[55]  A. Weverling-Rijnsburger,et al.  Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.

[56]  D. Molloy,et al.  Physician characteristics and prescribing for elderly people in New Brunswick: relation to patient outcomes. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[57]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[58]  E. Jones.  Disease , 2020, Palgrave Studies in Economic History.

[59]  J. Mant,et al.  Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. , 2014, The British journal of general practice : the journal of the Royal College of General Practitioners.

[60]  W. Assendelft,et al.  Time trends in preventive drug treatment after myocardial infarction in older patients. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[61]  B. Golomb,et al.  Statin Adverse Effects , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[62]  D. Atar,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invit , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[63]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[64]  D. Leys,et al.  Secondary prevention after ischemic stroke , 2005, Journal of Neurology.

[65]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003, European heart journal.

[66]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.